Our patients can schedule a COVID-19 vaccination through NYU Langone Health MyChart or the NYU Langone Health app. Learn more about the COVID-19 vaccine. Read our updated information about wearing a mask for your visit.

If you need help accessing our website, call 855-698-9991
Skip to main content

Auditory Brainstem Implants

Neurofibromatosis type 2 is a genetic disorder marked by the predisposition to develop a variety of tumors of the central and peripheral nervous system.

Sometimes these tumors can grow on the auditory nerve, which allows a person to hear. When the tumors are removed, the auditory nerve usually must be cut. As a result, a connection no longer exists between the still-functioning cochlea, the auditory portion of the inner ear, and the brain, causing hearing loss.

Audiologist Alison Singleton Holding Hearing Aid

An auditory brainstem implant (ABI) is used to stimulate the cochlear nucleus in people with neurofibromatosis type 2 whose hearing nerves don’t function. The procedure has been approved by the U.S. Food and Drug Administration (FDA).

Although people with neurofibromatosis type 2 tend to be completely deaf, and the benefit of an ABI is not as high as that of the cochlear implant, most recipients experience substantial improvement in hearing.

Auditory Brainstem Implant Project

We currently have an ongoing FDA-approved clinical trial for expanded use of the ABI device. Candidates are children without neurofibromatosis type 2, but who have absent or compromised hearing nerves or for any reason cannot benefit from a cochlear implant.

For more information about the Cochlear Implant Center, please call 212-263-7567. We’re located in Manhattan at 222 East 41st Street on the 8th floor. Learn more about our Otology and Neurotology Group.